NCT07021937

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 12 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Conditions

• Obesity/Therapy

Interventions

Type	Name	Description
DRUG	Semaglutide 1.7mg subcutaneous	Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
DRUG	Placebo	Placebo saline solution subcutaneous

Timeline

• Start date: 2026-05-01
• Primary completion: 2031-04-30
• Completion: 2031-04-30
• First posted: 2025-06-15
• Last updated: 2025-06-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study